RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...

Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...

Shares in drugmaker GSK surged on Thursday after it struck a 2.2 billion US dollar (£1.68 billion) settlement to resolve tens ...

(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...